Summary of HR 1266 - Combating Illicit Xylazine Act

Bill Overview

Bill Number: HR 1266

Title: Combating Illicit Xylazine Act

Status: Introduced in House

Introduced Date: February 12, 2025

Classification: Bill

The Combating Illicit Xylazine Act aims to address the growing concern surrounding the illicit use of xylazine, a veterinary sedative that has increasingly been found in illegal drug mixtures, particularly opioids. This legislation seeks to enhance federal efforts to combat the trafficking and misuse of this substance.

Purpose and Intent

The primary intent of HR 1266 is to:
- Control the distribution and use of xylazine by classifying it as a controlled substance.
- Mitigate the public health crisis associated with the rise of xylazine-laced drugs, which pose significant risks to users and complicate treatment efforts for substance use disorders.

Key Provisions

While the specific text of the bill is not provided, the following key provisions are anticipated based on the bill's intent:
- Classification of Xylazine: The bill will likely propose to schedule xylazine under the Controlled Substances Act, thereby regulating its manufacture, distribution, and possession.
- Increased Penalties: The legislation may introduce stricter penalties for trafficking and distributing xylazine, similar to those for other controlled substances.
- Funding for Research and Treatment: The bill may allocate resources for research into the effects of xylazine and for treatment programs aimed at individuals affected by its misuse.

Affected Parties

The Combating Illicit Xylazine Act would impact:
- Law Enforcement Agencies: Increased responsibilities in monitoring and enforcing regulations concerning xylazine.
- Healthcare Providers: Potential changes in treatment protocols for patients affected by xylazine use.
- Substance Use Disorder Programs: Programs may receive additional funding and resources to address the challenges posed by xylazine in the drug supply.

Legislative Process

• Introduced: The bill was introduced in the House on February 12, 2025.
• Committee Referral: It has been referred to the Committee on Energy and Commerce and the Committee on the Judiciary for further consideration. The timeline for subsequent actions will be determined by the Speaker of the House.

Related Legislation

HR 1266 has a companion bill in the Senate, S 545, which may provide additional context or support for similar measures aimed at controlling xylazine.

Conclusion

The Combating Illicit Xylazine Act represents a proactive legislative effort to address the emerging threat posed by xylazine in the illegal drug market. By regulating this substance, the bill aims to protect public health and enhance the effectiveness of treatment for those affected by substance use disorders.